Environmental, Social And Governance Report

Overview

The report highlights Genor's 2024 progress in advancing clinical and early-stage antibody pipelines, including GB491 regulatory milestones and GB268's pre-IND work. It describes international expansion through licensing GB261 to TRC 2004 and strategic cooperation with Edding. The company also reports a major operational restructuring, including closure of its Shanghai laboratory and Beijing office and outsourced manufacturing of investigational drugs. Reported 2024 total energy consumption was 82.02 MWh, while Scope 1 and Scope 2 emissions were 16.36 and 13.11 tCO 2e, respectively.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 28 March 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services